Bone And Connective Tissue Cancer
The researchers found that adipocytes absorbed and metabolized daunorubicin to daunorubicinol, which reduced its anti-leukemia effect. Daunorubicin conversion to daunorubicinol was confirmed in vivo in murine studies.
The Food and Drug Administration has granted accelerated approval to Lartruvo (olaratumab) injection with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS).
The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.
Daratumumab with bortezomib and dexamethasone is associated with longer progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma, according to a study published in the August 25 issue of the New England Journal of Medicine.
The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).
Daratumumab (Darzalex), a recently approved immunotherapy drug for multiple myeloma, can provide better benefits if patients receive it earlier in their treatment, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held in Chicago.
Older patients with soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do, according to research published in Anticancer Research.
In a case report published online February 28 in the Journal of Clinical Pharmacy and Therapeutics, researchers document non-HIV-associated Kaposi sarcoma in a male patient with myasthenia gravis and metastatic melanoma treated with the BRAF inhibitor dabrafenib.
Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.
The Food and Drug Administration (FDA) has approved Halaven (eribulin mesylate; Eisai) for the treatment of unresectable or metastatic liposarcoma in patients who have received prior chemotherapy containing an anthracycline.
The FDA has granted Breakthrough Therapy designation to pexidartinib (formerly PLX3397; Daiichi Sankyo/Plexxikon) for the treatment of tenosynovial giant cell tumor (TGCT) where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.
The Food and Drug Administration (FDA) has approved Yondelis (trabectedin; Janssen) for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.
The Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for eribulin mesylate (Eisai) for the treatment of patients with inoperable soft tissue sarcoma (leiomyosarcoma and liposarcoma) who have received prior chemotherapy for advanced or metastatic disease.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to dactinomycin nanoparticle formulation (NanoSmart) for the treatment of Ewing's sarcoma.
If genetic tests are only done on cancer tissue, as many as half of patients may not receive the most appropriate treatment for their cancer, according to new research.
Eisai announced results from a Phase 3 trial investigating the use of eribulin vs. dacarbazine in patients with advanced soft tissue sarcomas.
Treatment with pimecrolimus for eczema was found unlikely to increase the risk of cancer in children, according to a post-marketing study.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to its antinuclear antibody (ANA) conjugated liposomal doxorubicin (NanoSmart Pharmaceuticals) intended to treat Ewing's sarcoma, with potential expansion to other indications.
Janssen R&D and PharmaMar announced that the Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for Yondelis (trabectedin).
Amgen announced that the Food and Drug Administration (FDA) has approved Xgeva (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.
In a study of more than 1.1 million cancer patients who had surgery, Harvard researchers found that almost 5% died within one month of their operation.
About 14.5 million U.S. cancer survivors are alive today, compared to just three million in 1971, with prevention and targeted therapies helping to reduce mortality.
From 2000-2009 there was an increase in surgical treatment for spinal metastasis in the United States, which was accompanied by increased complication rates and costs.
A 12-year-old boy with a spinal injury stemming from bone cancer has received the first 3-D printed vertebra over a five-hour operation.
The risk for certain types of cancer seems to be linked to poverty or wealth and socioeconomic status should be considered in cancer surveillance.
For patients undergoing radiotherapy, shared decision-making and patient-perceived control in treatment decisions correlate with increased patient satisfaction.